Table of Contents
Hodgkin’s Lymphoma: Understanding the Causes, Symptoms, Cancer Stages, and Advances in Oncology
Introduction
Among the many forms of cancer, lymphoma is a type that affects the body’s lymphatic system, an essential component of the immune system. One of the most well-known forms of lymphoma is Hodgkin’s lymphoma (HL), a blood cancer that originates primarily from B lymphocytes and is characterized by the presence of Reed-Sternberg cells [1,2].
Although Hodgkin’s lymphoma is relatively uncommon, it is considered one of the most treatable cancers in modern oncology. Significant advancements in diagnosis, staging, and targeted therapies have led to excellent survival outcomes, with many patients achieving long-term remission and cure [1].
What is Hodgkin's Lymphoma?
Hodgkin’s lymphoma is a cancer of the lymphatic system, which includes lymph nodes, the spleen, bone marrow, and other immune tissues. The disease is broadly divided into two categories:
- Classical Hodgkin’s Lymphoma (cHL): Accounts for approximately 95% of all cases.
- Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma (NLPHL): A less common subtype that generally follows a slower clinical course [2,3].
The disease can occur at any age but is most frequently diagnosed in young adults and individuals above the age of 55 years [1,2].
Causes of Hodgkin Lymphoma Cancer
The exact causes of Hodgkin lymphoma cancer are not completely understood. However, researchers have identified several factors that may increase the likelihood of developing the disease.
Epstein-Barr Virus (EBV) Infection
Studies have shown an association between Hodgkin's lymphoma and prior infection with the Epstein-Barr virus, a common virus that can infect B lymphocytes [1,2].
Weakened Immune System
Individuals with conditions that affect the immune system, including HIV infection or those receiving long-term immunosuppressive treatment, may have a higher risk of developing Hodgkin's lymphoma [1,3].
Family History
A family history of Hodgkin's lymphoma may increase the risk of developing the disease, suggesting that genetic and environmental factors may both play a role [2].
Why Oral Mucositis Matters Beyond Mouth Sore
Although oral mucositis begins within the oral cavity, its consequences often extend far beyond local discomfort.
Severe oral mucositis may contribute to:
- Reduced food and fluid intake
- Weight loss and malnutrition
- Increased need for analgesics and supportive care
- Hospital admissions related to treatment complications
- Treatment interruptions or delays
- Chemotherapy dose reductions
- Reduced tolerance to planned cancer therapy
In severe cases, oral mucositis may compromise adherence to planned treatment schedules, highlighting the importance of preventive supportive care strategies.
For patients undergoing curative treatment, maintaining treatment intensity and schedule is often critical. Consequently, oral mucositis prevention and effective management of oral mucositis have become important goals of modern supportive oncology care.
Understanding the Biology of Oral Mucositis
Current research has shown that oral mucositis is not simply the result of direct injury to the oral lining.
Cancer therapies trigger a complex biological process involving:
- DNA and cellular damage
- Activation of inflammatory pathways
- Release of pro-inflammatory cytokines
- Breakdown of the mucosal barrier
- Changes in the oral microbial environment
- Delayed tissue repair and healing
These interconnected mechanisms contribute to the development and progression of oral ulcerations.
This improved understanding has shifted attention toward preventive strategies that target the underlying biological processes involved in mucositis development.
The Growing Role of Prevention in Oral Mucositis Management
Historically, management of oral mucositis focused primarily on supportive measures after symptoms appeared. These approaches continue to play an important role and include:
- Good oral hygiene practices
- Saline and bicarbonate mouth rinses
- Pain management
- Nutritional support
- Hydration maintenance
However, many experts now advocate earlier interventions aimed at reducing the severity of mucosal injury before extensive ulceration occurs.
The goal of preventive supportive care is to:
- Improve patient comfort
- Maintain nutritional status
- Reduce treatment-related complications
- Support treatment continuity
- Enhance overall quality of life
Oral Microbiome and Mucosal Health
The oral cavity contains a complex ecosystem of microorganisms collectively known as the oral microbiome. These microbial communities contribute to mucosal health, immune regulation, and maintenance of the oral barrier.
Cancer treatment can disrupt this delicate balance, leading to increased inflammation and impaired mucosal recovery. Emerging evidence suggests that dysbiosis of the oral microbiome may amplify inflammatory signalling and contribute to the severity of radiation-induced oral mucositis and chemotherapy-induced oral mucositis.
As a result, microbiome-focused approaches have become an area of growing interest in supportive cancer care.
Emerging Evidence for Probiotic-Based Approaches
As understanding of the oral microbiome grows, researchers are exploring whether targeted probiotic interventions can help maintain mucosal integrity during therapy and reduce the burden of oral mucositis in cancer patients.
Among microbiome-targeted interventions, specific probiotic strains have been investigated for their potential role in oral mucositis prevention.
One of the most extensively studied strains is Levilactobacillus brevis CD2. Research has suggested that this strain may help support oral mucosal health through modulation of inflammatory pathways, reduction of pro-inflammatory mediators, and maintenance of local microbial balance.
Clinical studies evaluating Levilactobacillus brevis CD2 in patients receiving radiotherapy, chemoradiotherapy, and hematopoietic stem cell transplantation have demonstrated reductions in the incidence and severity of oral mucositis compared with standard supportive care. These findings have contributed to growing scientific interest in probiotic-based supportive care strategies aimed at reducing treatment-related oral complications and improving patient experience during cancer therapy.
While additional research continues to expand the evidence base, microbiome-focused interventions represent an exciting development in the evolving field of supportive oncology.
Looking Ahead
Oral mucositis remains a significant challenge for patients undergoing chemotherapy and radiotherapy. Beyond causing painful mouth sores, it can affect nutrition, quality of life, and the ability to maintain planned cancer treatment.
As scientific understanding of mucositis continues to evolve, the focus is increasingly shifting from symptom management alone toward prevention and early supportive care. Advances in our understanding of the oral microbiome and mucosal biology are opening new opportunities to reduce treatment burden and improve patient outcomes.
As supportive oncology continues to evolve, prevention-focused strategies and microbiome-based approaches are becoming increasingly important in the management of oral mucositis in cancer patients. Continued research into oral mucosal biology and the oral microbiome may help identify new opportunities to reduce treatment-related complications and improve the overall patient experience during cancer therapy.
The future of supportive oncology lies not only in treating cancer effectively but also in preventing and managing treatment-related complications such as oral mucositis, helping patients maintain quality of life and remain on planned cancer therapy.
References
- Sonis ST. The Pathobiology of Mucositis. Nature Reviews Cancer. 2004.
- Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO Clinical Practice Guidelines for Mucositis Secondary to Cancer Therapy.
- Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO Clinical Practice Guidelines Update for the Management of Mucositis.
- Sharma A, Rath GK, Chaudhary SP, et al. Lactobacillus brevis CD2 Lozenges Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients with Head and Neck Cancer. European Journal of Cancer. 2012.
- Sharma A, et al. Effect of Lactobacillus brevis CD2 Lozenges in Preventing Oral Mucositis in Patients Undergoing High-Dose Chemotherapy Followed by Hematopoietic Stem Cell Transplantation. Indian Journal of Medical Research. 2017.